⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29617427 | 0.72 | — | — | |
| SCHEMBL27622531 | 0.69 | — | — | |
| SCHEMBL28042159 | 0.67 | — | — | |
| SCHEMBL12542798 | 0.64 | — | — | |
| SCHEMBL3885051 | 0.63 | — | — | |
| SCHEMBL3883020 | 0.63 | — | — | |
| SCHEMBL3384236 | 0.59 | — | — | |
| SCHEMBL26686729 | 0.59 | — | — | |
| SCHEMBL32667916 | 0.59 | — | — | |
| SCHEMBL28515136 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8847003-B2 | Role of proteoglycans in drug dependence | SANNA PIETRO P (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140173764-A9 | ROLE OF PROTEOGLYCANS IN DRUG DEPENDENCE | SANNA PIETRO P (US) | 2014-06-19 | — | — | US | disclosed |
| US-20120174240-A1 | ROLE OF PROTEOGLYCANS IN DRUG DEPENDENCE | SANNA PIETRO P (US) | 2012-07-05 | — | — | US | disclosed |
| US-8119854-B2 | Role of proteoglycans in drug dependence | Sanna, Pietro P. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20100199361-A1 | Role of Proteoglycans in Drug Dependence | Sanna, Pietro Paolo (US) | 2010-08-05 | — | — | US | disclosed |
| EP-1957112-A2 | ROLE OF PROTEOGLYCANS IN DRUG DEPENDENCE | Sanna, Pietro Paolo (US) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007062048-A2 | ROLE OF PROTEOGLYCANS IN DRUG DEPENDENCE | SCRIPPS RESEARCH INST (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20040180888-A1 | Phenylindoles for the treatment of HIV | IDENIX PHARMACEUTICALS INC. | 2004-09-16 | — | — | US | disclosed |
| US-20040023953-A1 | Tricylic mercaptomethyl-substituted 2,3-dihydro-quinazolin-5-ones and 2,3-dihydro-benzo-[1,2,4]-thiadiazin-5,5-dioxides as matrix metalloproteinase (MMP) inhibitors | IBFB GMBH PRIVATES INSTITUT FUR BIOMEDIZINISCHE FORSCHUNG UND BERATUNG (DE) | 2004-02-05 | — | — | US | disclosed |
| US-20040023953-A1 | Tricylic mercaptomethyl-substituted 2,3-dihydro-quinazolin-5-ones and 2,3-dihydro-benzo-[1,2,4]-thiadiazin-5,5-dioxides as matrix metalloproteinase (MMP) inhibitors | IBFB GMBH PRIVATES INSTITUT FUR BIOMEDIZINISCHE FORSCHUNG UND BERATUNG (DE) | 2004-02-05 | — | — | US | disclosed |
| EP-1319010-B1 | TRICYCLIC MERCAPTOMETHYL-SUBSTITUTED 2,3-DIHYDRO-QUINAZOLIN-5-ONES AND 2,3-DIHYDRO-BENZO-[1,2,4]-THIADIAZIN-5,5-DIOXIDES AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS | IBFB GMBH PRIVATES INST FUER B (DE) | 2003-12-17 | — | — | EP | disclosed |
| EP-1319010-A1 | TRICYCLIC MERCAPTOMETHYL-SUBSTITUTED 2,3-DIHYDRO-QUINAZOLIN-5-ONES AND 2,3-DIHYDRO-BENZO-[1,2,4]-THIADIAZIN-5,5-DIOXIDES AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS | IBFB GmbH Privates Institut für biomedizinische Forschung und Beratung (DE) | 2003-06-18 | — | — | EP | disclosed |
| WO-2002024710-A1 | TRICYCLIC MERCAPTOMETHYL-SUBSTITUTED 2,3-DIHYDRO-QUINAZOLIN-5-ONES AND 2,3-DIHYDRO-BENZO-[1,2,4]-THIADIAZIN-5,5-DIOXIDES AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS | IBFB GMBH PRIVATES INSTITUT FÜR BIOMEDIZINISCHE FORSCHUNG UND BERATUNG (DE) | 2002-03-28 | — | — | WO | disclosed |